DIAGNOSIS AND MANAGEMENT OF INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA: GUIDELINE ENDORSED BY ITALIAN SOCIETY OF INFECTION AND TROPICAL DISEASES (SIMIT), THE ITALIAN SOCIETY OF ANTI-INFECTIVE THERAPY (SITA), THE ITALIAN GROUP FOR ANTIMICROBIAL STEWARDSHIP (GISA), THE ITALIAN ASSOCIATION OF CLINICAL MICROBIOLOGIST (AMCLI) AND THE ITALIAN SOCIETY OF MICROBIOLOGY (SIM).

/0 Commenti/in , , /da
Continua a leggere

OlympiA: A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ADJUVANT OLAPARIB AFTER (NEO)ADJUVANT CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA1 AND/OR BRCA2 PATHOGENIC VARIANTS AND HIGH RISK HER2-NEGATIVE PRIMARY BREAST CANCER: LONGER TERM FOLLOW-UP

/0 Commenti/in , , /da
Continua a leggere

FIRST-LINE MOBOCERTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH EGFR EXON 20 INSERTION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER IN THE PHASE III EXCLAIM-2 TRIAL

/0 Commenti/in , , /da
Continua a leggere

FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.

/0 Commenti/in , , /da
Continua a leggere

PHASE II EFFICACY AND SAFETY OF 80 MG OSIMERTINIB IN PATIENTS WITH LEPTOMENINGEAL METASTASES ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (BLOSSOM).

/0 Commenti/in , , /da
Continua a leggere

FIRST-LINE NIVOLUMAB PLUS RELATLIMAB VERSUS NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA: AN INDIRECT TREATMENT COMPARISON USING RELATIVITY-047 AND CHECKMATE 067 TRIAL DATA.

/0 Commenti/in , , /da
Continua a leggere